CATALYST BIOSCIENCES INC CBOE ($CBIO)
CBIO will release at the ISTH conference final Phase 2 data for marzeptaacog alfa in hemophilia.Dr. Johnny Mahlangu, M.D., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator on the MarzAA Phase 2...
short term target on chart
see some MOMO until FDA news coming out
07/18/2018
Phase 2 commencement of Part 2 of Phase 2/3 trial announced January 4, 2018. Interim data due at ISTH July 18, 2018. Final data due at ASH 2018.
potential gapper candidate
cbio has been popping up multiple times on my scans playing around in my action zone between the 10ma and 30ema with 5 consecutive down days + nr7 inside day on low volume. Looks to be holding those supports quite well, triangulating and Volume has been drying up nicely. I would normally like to get in just above that inside days high but with current market...
CBIO seems forming a very nice fallen angel formation. It has history of sharp breakout, and at this time it seems getting ready for another breakout. We are looking for a quick day trade if it breaks above $4.70
* Trade Criteria *
Date First Found- June 29, 2017
Pattern/Why- Fallen angel formation
Entry Target Criteria- Break of $4.70
Exit Target Criteria-...
U.S. Government Required Disclaimer - Commodity Futures Trading Commission Futures, Stocks and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation...
$CBIO Recent Highlights and Upcoming Milestones
Recent Highlights:
Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis...
Why did CBIO stock shares practically triple? On longer charts,stock worth over $3,000 share once.
Catalyst Biosciences Inc. (CBIO) saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval. The company reported that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug...
Reverse Merger took place in September
7/1 Stock Split on 8/25 took Sh.P. from $12-8
Bottomed out 12/18 on HUGE Volume Surge
This likely to do with insider purchasing creating a base @ $2.00
Watch a possible bounce
1st breather: $3.09
18.39% Return
2nd breather: $3.39
29.89% Return
*See technicals for entry and exit
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
CBIO
